Effect of Rifampicin on the Pharmacokinetics of BI 409306 Following Oral Administration in Healthy Male Subjects (an Open-label, Two-period, Fixed Sequence Trial)

Trial Profile

Effect of Rifampicin on the Pharmacokinetics of BI 409306 Following Oral Administration in Healthy Male Subjects (an Open-label, Two-period, Fixed Sequence Trial)

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs BI 409306 (Primary) ; Rifampicin
  • Indications Alzheimer's disease; Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 20 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 01 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top